Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics (NQ: MRTX )

40.50 +1.09 (+2.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mirati Therapeutics

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Investor Alert: Investigation over Possible Breaches of Fiduciary Duties
San Diego, CA -- (SBWIRE) -- 05/11/2023 -- Certain directors of Mirati Therapeutics, Inc are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech... 
Via FinancialNewsMedia
Topics Death
Exposures Death
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
From Incyte and Mirati
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Mirati Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Investigation Announced for Long-Term Investors in Mirati Therapeutics, Inc. (NASDAQ:MRTX)
San Diego, CA -- (SBWIRE) -- 12/07/2021 -- Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
NASDAQ:MRTX Investor Notice: Investigation over Possible Securities Laws Violations by Mirati Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 11/08/2021 -- Mirati Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Topics Regulatory Compliance
Exposures Legal Regulatory
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
From QIAGEN N.V.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.